MELBOURNE, Australia, June 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for ...
The companies will combine their complementary expertise in synthetic oligosaccharides, conjugation process development and GMP vaccine manufacturing to support partners developing next-generation ...
SHANGHAI, Aug. 30, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has ...
STONY BROOK, NY / ACCESSWIRE / January 10, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the completion of ...
Hosted on MSN
GMP manufacturing sale gives MacroGenics additional non-dilutive capital for pipeline development (MGNX)
MacroGenics agreed to sell its GMP manufacturing operations to Bora Pharmaceuticals in a deal designed to strengthen its balance sheet and sharpen focus on its oncology pipeline. ・MacroGenics ...
(NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, and Bora Pharmaceuticals Co., Ltd. (TWSE: 6472; ...
Pre-production, Engineering Run and GMP Manufacture of PRP in 2026 MELBOURNE, Australia, June 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results